Analisis Minimalisasi Biaya Penggunaan Psikotropika pada Pasien Remaja dengan Disabilitas Intelektual di Rumah Sakit Jiwa Provinsi Jawa Barat Tahun 2015–2017
Abstract
Obat-obatan psikotropika merupakan obat-obatan yang paling banyak digunakan pada pasien remaja dengan disabilitas intelektual di RS Jiwa Provinsi Jawa Barat. Penelitian farmakoekonomi pada topik ini penting dilakukan karena adanya peningkatan kebutuhan anggaran obat-obatan psikotropika sementara anggaran yang tersedia masih terbatas. Tujuan penelitian ini adalah untuk mengetahui profil penggunaan obat-obatan psikotropika pada pasien remaja dengan disabilitas intelektual di rumah sakit tersebut pada kurun waktu tahun 2015–2017 dan untuk mengetahui biaya obat-obatan psikotropika yang paling rendah pada segmen drug utilization 90% (DU 90%) pada tahun-tahun tersebut. Studi observasional deskriptif secara retrospektif dan prospektif dilakukan untuk mengumpulkan data dari rekam medik. Metode Anatomical Therapeutic Chemical Classification with Defined Daily Dose (ATC/DDD) dan Analisis Minimalisasi Biaya (AMiB) digunakan untuk mengetahui profil penggunaan obat-obatan dan untuk menganalisis biaya obat-obatan yang paling rendah selama kurun waktu tersebut. Pada penelitian ini, terdapat penggunaan 33 jenis obat psikotropika (19 jenis pada tahun 2015, 22 jenis pada tahun 2016 dan 29 jenis pada tahun 2017). Cost of DU 90% pada tahun 2015–2017 secara berurutan yaitu 55,11%, 68,73% dan 93,81%, sedangkan cost/DDD segmen DU 90% secara berurutan yaitu Rp6.258, Rp7.447, dan Rp8.803. Biaya obat-obatan psikotropika pada tahun 2015 merupakan biaya terendah selama 2015–2017.
Kata kunci: Analisis minimalisasi biaya, disabilitas intelektual, psikotropika
Cost-Minimization Analysis of Psychotropic Drug in Adolescent Patients with Intellectual Disability in Mental Hospital of West Java 2015–2017
Abstract
Psychotropic drugs were one of the the most widely used drugs in adolescent patients with intellectual disability in Mental Hospital of West Java. Pharmacoeconomic study on this topic is important because budget for psychotropic drugs need is increased while the available budget is still limited. The objective of this study was to analyze the utilization profile of psychotropic drugs in adolescents with intellectual disability during a time horizon of 2015–2017 and to investigate the lowest cost of psychotropic drugs in a segment of drug utilization 90% (DU 90%) during those years. Retrospective and prospective observational studies were applied to collect patients’ medical record data. The Anatomical Therapeutic Chemical Classification System with Defined Daily Dose (ATC/DDD) and Cost Minimization Analysis (CMA) methods were applied to analyse the utilization profile of drugs and to investigate the lowest cost of drugs during the time horizon, respectively. In this study, there were 33 types of psychotropic drugs used (19 types in 2015, 22 types in 2016, and 29 types in 2017). The costs of DU 90% during 2015–2017 were estimated to be 55.11%, 68.73% and 93.81% in 2015, 2016 and 2017, respectively, while the costs per DDD in DU 90% segment were estimated to be IDR 6,258, IDR 7,447, and IDR 8,803, respectively. In particular, cost of psychotropic drugs in 2015 was considered to be the lowest cost during 2015–2017.
Keywords: Cost-minimization analysis, intellectual disability, psychotropic drug
Keywords
Full Text:
PDF (Bahasa Indonesia)References
American Association on Intellectual and Developmental Disabilities. Definition of intellectual disability [Accessed on: 28 February 2018]. Available at: http://aaidd.org/intellectual-disability/definition#.WpZ4BCklHIW
Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: A meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419–36. doi: 10.1016/j.ridd.2010.12.018
Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. Situasi penyandang disabilitas. Buletin Jendela Data dan Informasi Kesehatan. 2014;1–18.
LoVullo SV, Matson JL. Comorbid psychopathology in adults with autism spectrum disorders and intellectual disabilities. Res Dev Disabil. 2009;30(6):1288 –96. doi: 10.1016/j.ridd.2009.05.004.
Einfeld SL, Ellis LA, Emerson E. Comorbidity of intellectual disability and mental disorder in children and adolescents: A systematic review. J Intellect Dev Disabil. 2011;36(2):137–43. doi: 10.1080/13668250.2011.572548.
Tsiouris JA, Kim SY, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. J Autism Dev Disord. 2013;43(3):719-31. doi: 10.1007/s10803-012-1617-6.
Bertelli MO, Rossi M. Update on psychopharmacology for persons with intellectual disability and/or low functioning autism spectrum disorder. J Mental Health Res Intellectual Disabil. 2017;10(1):31–3. doi: 10.1108/AMHID-10-2015-0049
Matson JL, Neal D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Res Dev Disabil. 2009;30(3):572–86. doi: 10.1016/j.ridd.2008.08.007.
Romeo R, Molosankwe I. Economic evidence in intellectual disabilities: A review. Curr Opin Psychiatr. 2010;23(5):427–31. doi: 10.1097/YCO.0b013e32833ad946
Shaughnessy TM, Parker FR, Hollenshead JH, Clottey EN, Rubin HW. Contemporary data and trends in the economic costs of mental disabilities. Behav Sci Law. 2017;35(2):162-177. doi: 10.1002/bsl.2280.
Doran CM, Einfeld SL, Madden RH, Otim M, Horstead SK, Ellis LA, et al. How much does intellectual disability really cost? First estimates for Australia. J Intellect Dev Disabil. 2012;37(1):42–9. doi: 10.3109/13668250.2011.648609.
Havighurst R. Developmental tasks and education (3rd Edit.) New York: David McKay Co; 1972.
Ghaffary S, Maleki TE, Abdollahpor J, Hamishehkar H. Measurement and comparison of inpatient antibiotic use in five different hospitals in Tabriz. Pharm Sci. 2017;23(1):37-41 doi: 10.15171/PS.2017.06
World Health Organization. Collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment 2017. Oslo: World Health Organization; 2016.
Kementerian Kesehatan Republik Indonesia. Pedoman teknis analisis farmakoekonomi di fasilitas kesehatan. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016.
Maenner MJ, Blumberg SJ, Kogan MD, Christensen D, Yeargin-Allsopp M, Schieve LA. Prevalence of cerebral palsy and intellectual disability among children identified in two US National Surveys, 2011–2013. Ann Epidemiol. 2016;26(3):222–6. doi: 10.1016/j.annepidem.2016.01.001
Westerinen H, Kaski M, Virta LJ, Kautiainen H, Pitkälä KH, Iivanainen M. The nationwide register-based prevalence of intellectual disability during childhood and adolescence. J Intellect Disabil Res. 2017;61(8):8029. doi: 10.1111/jir.12351
Bourke J, de Klerk N, Smith T, Leonard H. Population-based prevalence of intellectual disability and autism spectrum disorders in Western Australia: A comparison with previous estimates. Medicine. 2016;95(21):e3737. doi: 10.1097/MD.0000000000003737.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009;373(9657):31–41. doi: 10.1016/S0140-6736(08)61764-X.
Perry BI, Kwok HF, Mendis J, Purandare K, Wijeratne A, Manjubhashini S, et al. Problem behaviours and psychotropic medication use in intellectual disability: A multinational cross-sectional survey. J Intellect Disabil Res. 2018;62(2):140–9. doi: 10.1111/jir.12471.
Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016;29(2):103–25. doi: 10.1097/YCO.0000000000000233.
Capone GT, Goyal P, Grados M, Smith B, Kammann H. Risperidone use in children with down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study. J Dev Behav Pediatr. 2008;29(2):106–16. doi: 10.1097/DBP.0b013e318165c100.
Unwin GL, Deb S. Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Res Dev Disabil. 2011;32(6): 2121 –33. doi: 10.1016/j.ridd.2011.07.031.
Cohen D, Raffin M, Canitano R, Bodeau N, Bonnot O, Périsse D, et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord. 2013;7(1):167–75. doi: 10.1016/j.rasd.2012.08.001
McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: A systematic review and meta-analysis. BMC Psychiatry. 2015;15(1):303. doi: 10.1186/s12888-015-0688-2.
Pisano S, Catone G, Veltri S, Lanzara V, Pozzi M, Clementi E, et al. Update on the safety of second generation antipsychotics in youths: A call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr. 2016;42(1):51. doi: 10.1186/s13052-016-0259-2
Sheehan R, Horsfall L, Strydom A, Osborn D, Walters K, Hassiotis A. Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ open. 2017;7(8):e017406. doi: 10.1136/bmjopen-2017-017406
Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1):20. doi: 10.1186/1471-244X-12-20.
Luskin AT, Antonova EN, Broder MS, Chang EY, Omachi TA, Ledford DK. Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: A claims-based analysis. Clinicoecon Outcomes Res. 2016;8:641–8. doi: 10.2147/CEOR.S115025
Azmi AN, Desrini S. A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy. Jurnal Kedokteran dan Kesehatan Indonesia. 2016;7(3):102–8. doi: 10.20885/JKKI.Vol7.Iss3.art5
O’Dwyer M, Peklar J, Mulryan N, McCallion P, McCarron M, Henman MC. Prevalence and patterns of anti-epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities. J Intellect Disabil Res. 2018;62(3):245–61. doi: 10.1111/jir.12461
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–25.
Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, et al. Donepezil significantly improves abilities in daily lives of female down syndrome patients with severe cognitive impairment: A 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med. 2011;41(1):71–89. doi: 10.2190/PM.41.1.g
Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, et al. Efficacy and safety of donepezil in chinese patients with severe alzheimer’s disease: A randomized controlled trial. J Alzheimers Dis. 2017;56(4):1495–504. doi: 10.3233/JAD-161117.
Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17. Am J Med Genet A. 2010;152A(12):3028-35. doi: 10.1002/ajmg.a.33730.
Tamasaki A, Saito Y, Ueda R, Ohno K, Yokoyama K, Satake T, et al. Effects of donepezil and serotonin reuptake inhibitor on acute regression during adolescence in down syndrome. Brain Dev. 2016;38(1):113–7. doi: 10.1016/j.braindev.2015.06.006.
Bank Sentral Republik Indonesia. Inflation report (consumer price index) base on year on year measurement [Accessed on: 22 December 2017]. Available at: http://www.bi.go.id/en/moneter/inflasi/data/De fault.aspx
DOI: https://doi.org/10.15416/ijcp.2018.7.3.180
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
